EP1734983A4 - MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS - Google Patents

MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS

Info

Publication number
EP1734983A4
EP1734983A4 EP05725390A EP05725390A EP1734983A4 EP 1734983 A4 EP1734983 A4 EP 1734983A4 EP 05725390 A EP05725390 A EP 05725390A EP 05725390 A EP05725390 A EP 05725390A EP 1734983 A4 EP1734983 A4 EP 1734983A4
Authority
EP
European Patent Office
Prior art keywords
methods
preventing thrombosis
modified annexin
annexin proteins
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05725390A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1734983A2 (en
Inventor
Anthony Allison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alavita Pharmaceuticals Inc
Original Assignee
Alavita Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alavita Pharmaceuticals Inc filed Critical Alavita Pharmaceuticals Inc
Publication of EP1734983A2 publication Critical patent/EP1734983A2/en
Publication of EP1734983A4 publication Critical patent/EP1734983A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP05725390A 2004-03-11 2005-03-10 MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS Withdrawn EP1734983A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55242804P 2004-03-11 2004-03-11
US57958904P 2004-06-14 2004-06-14
PCT/US2005/008193 WO2005086955A2 (en) 2004-03-11 2005-03-10 Modified annexin proteins and methods for preventing thrombosis

Publications (2)

Publication Number Publication Date
EP1734983A2 EP1734983A2 (en) 2006-12-27
EP1734983A4 true EP1734983A4 (en) 2009-11-18

Family

ID=34976262

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05725390A Withdrawn EP1734983A4 (en) 2004-03-11 2005-03-10 MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS

Country Status (5)

Country Link
EP (1) EP1734983A4 (enExample)
JP (2) JP5134362B2 (enExample)
AU (1) AU2005221195B2 (enExample)
CA (1) CA2559167A1 (enExample)
WO (1) WO2005086955A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
EP2328622B1 (en) 2008-08-26 2014-12-17 MosaMedix B.V. Radiolabelled annexins
WO2013022328A1 (en) * 2011-08-09 2013-02-14 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN117897399A (zh) * 2021-06-14 2024-04-16 Inserm(法国国家健康医学研究院) 突变的膜联蛋白a5多肽及其在治疗目的中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JP3742675B2 (ja) * 1995-06-28 2006-02-08 東菱薬品工業株式会社 虚血−再灌流障害の予防および治療薬
CA2331789C (en) * 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
CN1125084C (zh) * 1999-03-12 2003-10-22 中国科学院上海生物化学研究所 一种血栓靶向性溶栓融合蛋白
WO2003103577A2 (en) * 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JIE LIU ET AL: "Annexin V assay-proven anti-apoptotic effect of ascorbic acid 2-glucoside after cold ischemia/reperfusion injury in rat liver transplantation.", ACTA MEDICA OKAYAMA, vol. 57, no. 5, 1 October 2003 (2003-10-01), pages 209 - 216, XP055051694, ISSN: 0386-300X *
KIMBERLEY E. WEVER ET AL: "Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic Tissue", PLOS ONE, vol. 6, no. 8, 1 January 2011 (2011-01-01), pages e24276, XP055031079, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0024276 *
KUYPERS FRANS A ET AL: "Interaction of an annexinV homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity", THROMBOSIS AND HAEMOSTASIS, vol. 97, no. 3, March 2007 (2007-03-01), pages 478 - 486, XP009123428, ISSN: 0340-6245 *
LA ET AL: "Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action", THE FASEB JOURNAL, vol. 15, no. 12, 1 October 2001 (2001-10-01), pages 2247 - 2256, XP055000646, ISSN: 0892-6638, DOI: 10.1096/fj.01-0196com *
SHEN X-D ET AL: "Diannexin, A Novel Annexin V Homodimer, Protects Rat Liver Transplants Against Cold Ischemia Reperfusion Injury", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD, DK, vol. 7, no. 11, 1 November 2007 (2007-11-01), pages 2463 - 2471, XP008101571, ISSN: 1600-6135, [retrieved on 20071009] *
TEOH ET AL: "Diannexin, a Novel Annexin V Homodimer, Provides Prolonged Protection Against Hepatic Ischemia-Reperfusion Injury in Mice", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 133, no. 2, 3 August 2007 (2007-08-03), pages 632 - 646, XP022198888, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2007.05.027 *
TODUKA MASAYUKI ET AL: "Mobilization of cardiac annexin V during ischemia and ischemic reperfusion", DOKKYO JOURNAL OF MEDICAL SCIENCES, MIBU, JP, vol. 27, no. 1, 1 March 2000 (2000-03-01), pages 253 - 260, XP009166718, ISSN: 0385-5023 *
WOLBERG ALISA S ET AL: "Annexin A2: better left alone.", BLOOD 1 MAR 2005, vol. 105, no. 5, 1 March 2005 (2005-03-01), pages 1845 - 1846, XP002547852, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2005086955A2 (en) 2005-09-22
CA2559167A1 (en) 2005-09-22
AU2005221195A1 (en) 2005-09-22
EP1734983A2 (en) 2006-12-27
JP2008502592A (ja) 2008-01-31
AU2005221195B2 (en) 2011-05-19
JP2012254992A (ja) 2012-12-27
JP5134362B2 (ja) 2013-01-30
WO2005086955A3 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
EG25848A (en) Systems and methods for protein production
AP2007003890A0 (en) Antibodies directed against amy-loid-beta peptide and methods using same
IL191820A0 (en) Anti-ox40l antibodies and methods using same
IL184308A0 (en) Systems and methods for providing
IL181278A0 (en) Systems and methods for protein production
EP1748721A4 (en) DISHWASHER AND METHOD
GB0404731D0 (en) Method and products for the selective degradation of proteins
PL2476318T3 (pl) Ser i sposoby wytwarzania sera
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
EP1734983A4 (en) MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS
GB0516058D0 (en) New protein isoforms and uses thereof
GB0424552D0 (en) Methods and means
GB0417887D0 (en) Protein
GB0403847D0 (en) Methods and means
GB0416699D0 (en) Prion protein ligands and methods of use
GB0410710D0 (en) Inspection system and method
EP1760149A4 (en) PROCESS FOR CONSTRUCTING MODIFIED PROTEIN
GB0421911D0 (en) Methods and means
GB0401882D0 (en) Protein
GB0404929D0 (en) Protein
GB0419181D0 (en) Methods and means
GB0423658D0 (en) Methods and means
GB0421466D0 (en) Methods and means
GB0425081D0 (en) Methods and means
GB0427483D0 (en) Methods and means

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061005

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/02 20060101ALI20091007BHEP

Ipc: A61K 38/17 20060101AFI20061016BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091016

17Q First examination report despatched

Effective date: 20111109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903